BioTek Receives Extraordinary New Product Line Award from Fisher
News Mar 04, 2014
BioTek Instruments, Inc. has received Thermo Fisher Scientific's "Extraordinary New Product Line" award for their Cytation 3 Cell Imaging Multi-Mode Reader.
The award was presented at the Fisher Scientific North America Sales Meeting, held February 24-26, 2014 in Denver, Colorado.
Cytation 3 was recognized by Fisher Scientific's product management team for its innovative technology and successful sales performance.
"We're proud to have Fisher Scientific as a strong partner, and honored to receive this award," noted Gary Barush, Director of Marketing and Sales at BioTek Instruments. "Together, and with Cytation 3's combination of cellular imaging and multi-mode microplate detection, we can continue to provide unique workflow solutions to any laboratory."
BioTek's patent pending Cytation™ 3 Cell Imaging Multi-Mode Reader combines automated digital fluorescence microscopy and conventional microplate detection in a modular and upgradable platform.
This allows for quantitative and phenotypic cellular analyses, and especially for live cell assays where Cytation 3's temperature control and available gas control module support the ideal environment to grow, image, count and further analyze cells in microplates and other sample vessels.
Cytation 3 is the recipient of two additional awards since its launch: MipTec New Product Innovation Award and the SelectScience "Scientists' Choice Award for Best Drug Discovery Product" Award. It is also a finalist in the 2014 Edison Awards® competition.
Chemical Compound Class Possesses Potential for Treating Zika VirusNews
A new and promising class of chemical compounds has major potential for treating Zika virus and respiratory syncytial virus, or RSV, according to a new study.READ MORE
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE
BioAscent Secures Investment to Expand its Integrated Drug Discovery ServicesNews
£1.6m investment recognises BioAscent’s unique capabilities.READ MORE